NorwayNorway

Clavis pharma licences thyroid cancer compound

17.05.2011

Oslo – Clavis Pharma ASA has signed a licensing deal with US firm Translational Therapeutics, Inc., for the development and commercialization of CP-4033, a patented Lipid Vector Technology (LVT) derivative of ribavirin under preclinical development at Clavis. Under the terms of the agreement, Translational Therapeutics will be responsible for all future development of the drug formulation, which targets the eIF4E oncogene, as a treatment of aggressive thyroid cancer. Additionally, Translational Therapeutics has the option to evaluate the formulation’s potential in other solid tumour indications. Clavis Pharma will receive a minority equity stake in Translational Therapeutics and potential future milestone and royalty payments. Financial terms of the agreement were not disclosed. Preclinical studies with CP-4033 conducted by Translational Therapeutics suggest that CP-4033 may be even more effective than ribavirin at inhibiting eIF4E’s oncogenic activities. Elevated elF4E activity is believed to play a role in about 30% of human cancers.

NorwayNorway

10.06.2009

Oslo/Toulouse – The Norwegian Oslo Cancer Cluster and French Toulouse Cancer-Bio-Sante Cluster have announced they will be strengthening their collaboration. As a first step, the two are hosting a new conference to be held on...

NorwayNorway

07.06.2009

Oslo – Bjarte Reve, the CEO of the Oslo Cancer Cluster and also one of the 200 World Economic Forum’s 2009 Young Global Leaders, wants to use his new title to accelerate the development of better cancer diagnostics and treatments...

NorwayNorway

15.05.2009

Oslo – After assessing a variety of criteria, including efficacy in the prevention of cervical cancer, safety and evidence of long-lasting protection, Norwegian health authorities have chosen Sanofi Pasteur MSD’s Gardasil for the...

NorwayNorway

21.02.2009

Kalundborg – In January, Norwegian pharmaceutical company Pronova Bio-pharma ASA began recruiting employees for its new Danish plant, which is slated to go into operation within a year. In 2007, Pronova invested a200m in the port...

NorwayNorway

20.02.2009

Oslo – At the end of January, the Norwegian government put forward a biotech crisis package with a total volume of up to a150m. Key measures include an increased funding of innovation loans from the industrial development agency...

NorwayNorway

20.02.2009

Norwegian cancer therapeutics company Algeta ASA has announced plans to raise EUR27.7m (NOK 245m) through the private placement of 22.3 million new shares in a move managed by ABG Sundal Collier and DnB NOR Markets. Directed at...

NorwayNorway

21.01.2009

The Norwegian government is discussing a €300m rescue package for the biotech industry as part of a national financial rescue plan. The proposal for the plan was put forward by the academic institutes, hospitals and businesses...

NorwayNorway

19.08.2008

Oslo – Photocure ASA, one of the Norwegian biotech companies established around the Radium Hospital in Oslo, has finished its demerger and set up a new company named PCI Biotech. In June, the former subsidary raised EUR7.6m (NOK...

NorwayNorway

14.08.2008

Svalbard – During a two-day journey to the Arctic in June, German Research Minister Annette Schavan delivered 17,000 seed samples to the Norwegian Svalbard Global Seed Vault, which was opened in 2007. The samples were mainly...

NorwayNorway

14.08.2008

Oslo –Algeta A/S has started a Phase III study of its bone-targeting radium-223 drug Alpharadin that will enrol 750 men with advanced, hormone-refractory prostate cancer (HRPC). The primary efficacy endpoint of the trial is...

Displaying results 31 to 40 out of 92

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/3/article/clavis-pharma-licences-thyroid-cancer-compound.html

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events